Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ijlh.12322 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Circulating large extracellular vesicles as diagnostic biomarkers of indeterminate thyroid nodules: multi-platform omics analysis.
BJS Open
December 2024
Institute of Cardiovascular Sciences, University College London, London, UK.
Background: While most thyroid nodules are benign, 7-15% are malignant. Patients with indeterminate thyroid nodules (specifically Bethesda IV/Thy3f) often undergo diagnostic hemithyroidectomy to reach a diagnosis on final histology. The aim of this study was to assess the feasibility of circulating large extracellular vesicles as diagnostic biomarkers in patients presenting with Thy3f thyroid nodules.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
University of California San Francisco (UCSF), San Francisco, CA, USA.
Background: As new anti-amyloid immunotherapies emerge for Alzheimer's disease (AD), it is clear that early diagnosis of AD pathology is crucial for treatment success. This can be challenging in atypical presentations of AD and, together with our reliance on CSF or PET scans, can, at times, lead to delayed diagnosis. Here, we further explore the possible role of plasma tau phosphorylated at threonine 217 (P-tau217) for the detection of primary AD or AD co-pathology when frontotemporal dementia spectrum disorders are the main clinical presentation.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Douglas Mental Health University Institute, Centre for Studies on the Prevention of Alzheimer's Disease (StoP-AD), Montréal, QC, Canada.
Background: Amyloid-negative tau-positive PET (A-T+) participants have been reported in several studies. We assessed the prevalence and characteristics of A-T+ participants in a cohort of cognitively unimpaired individuals with a first-degree family history of Alzheimer's disease (AD) dementia.
Method: We studied 252 participants from the longitudinal PREVENT-AD cohort (mean cognitive follow-up = 3.
Biomarkers.
Alzheimers Dement
December 2024
Translational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, Montréal, QC, Canada.
Background: Biomarkers promise to significantly improve the differential diagnosis of Alzheimer's disease (AD). Plasma biomarkers, such as phosphorylated tau (p-tau), have shown potential in diagnosing AD with high accuracy. Unlike the widely-used [18 F]FDG-PET diagnostic biomarker in clinical practice, plasma p-tau is specific to AD and can provide an affordable and scalable diagnostic tool.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Waisman Center, University of Wisconsin-Madison, Madison, WI, USA.
Background: Blood-based biomarkers able to detect atypical neuropathology could serve as a cost-effective and noninvasive screening to include participants with Down syndrome (DS) in anti-amyloid clinical trials. Accurately placing these novel biomarkers on the AD pathological cascade as proposed by the AT(N) framework informs relative disease progression of individuals. This work examines associations between plasma pTau217 accumulation, PET amyloid positivity, and cognitive status in adults with Down syndrome.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!